Cytokine release assays: current practices and future directions.

Area of Science:

• Immunotoxicology
• Biopharmaceutical Safety Assessment
• Drug Development

Background:

• The CD28 superagonist TGN 1412 incident underscored the need for robust cytokine release assays (CRA).
• CRAs are vital for hazard identification and risk assessment of novel biotherapeutics.
• Variability exists in CRA strategies, formats, and data interpretation across laboratories.

Purpose of the Study:

• To provide an overview of diverse CRA approaches used by the pharmaceutical industry and contract research organizations (CROs).
• To discuss ongoing academic research, the regulatory landscape, and current assay limitations.
• To offer recommendations for the future development and application of CRAs.

Main Methods:

• Survey and follow-up conducted by the ILSI-HESI Immunotoxicology Committee CRA Working Group.
• Review of practices employed by pharmaceutical companies, CROs, academic, and government laboratories.
• Analysis of data reporting, interpretation, and decision-making processes.

Main Results:

• Significant variation in CRA methodologies and data utilization exists.
• Practices are evolving to generate data predictive of in vivo human responses.
• Regulatory submissions increasingly incorporate CRA data, though standardization is pending.

Conclusions:

• Standardization of CRA methodologies and data interpretation is needed.
• Further research is essential to enhance the predictive power of CRAs for clinical safety.
• Collaborative efforts are crucial for advancing CRA applications in biotherapeutic development.